Cardiothoracic & vascular anesthesia
Remimazolam to prevent hemodynamic instability during catheter ablation under general anesthesia: a randomized controlled trial
Primary resultResult — go to the resultRelative risk 0.5 95% CI 0.31–0.83Authors' conclusion
Remimazolam-based total intravenous anesthesia was associated with significantly fewer hypotensive events and vasopressor requirements than desflurane-based inhalational anesthesia was, without significantly more complications.
Study context
- Population
- Patients undergoing cardiac ablation for arrhythmia under GA
- Participants
- 96 patients
- Comparison
- Remimazolam vs Desflurane
- Remimazolamn = 47
- Desfluranen = 49reference
- Primary endpoint
- Intraoperative hypotensive events (MAP < 60 mm Hg at any period)
Methodological detailssingle-centre, parallel-group, prospective, single-blind
- Single-centre
- Parallel-group
- Prospective
- Single-blind
Primary result
As reported in the abstract
Relative risk
0.5
95% CI 0.31–0.83
P = 0.004
Events by treatment group
Remimazolam vs Desflurane
RR 0.5 (95% CI 0.31–0.83); P = 0.004
Further findings
| Outcome | Remimazolam | Desflurane | RR (95% CI) | P value | |
|---|---|---|---|---|---|
| Bolus or continuous vasopressor requirement | 49% | 88% | 0.56 (0.41–0.76) | P < 0.001 | |
| 0.512Relative risk (log scale) |
Safety
Perioperative complications (nausea, vomiting, oxygen desaturation, delayed emergence, pain)
- No between-group differences
Original publication
Remimazolam to prevent hemodynamic instability during catheter ablation under general anesthesia: a randomized controlled trial. Can J Anaesth. Published 12 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →